Dental Care Clinics in Ansonia, CT Accepting Medicare
6 Dental Care Clinics found. Showing 1 - 6
 Southern Connecticut Dental Group Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 497 Main St, Ansonia, CT 06401 Phone: 203-735-4701 Fax: 203-736-9443 |
Marshall S. Greenberg, D.m.d., P.c. Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 201 Division St, Ansonia, CT 06401 Phone: 203-735-9600 Fax: 203-954-0014 |
Dr Robert L Lerman Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 497 Main St, Ansonia, CT 06401 Phone: 203-735-4701 |
42 North Dental Care, Pllc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 497 Main St, Ansonia, CT 06401 Phone: 203-735-4701 |
David D. Millen, D.m.d. Pc Dentist - Periodontics Medicare: Not Enrolled in Medicare Practice Location: 560 Main Street, Ansonia, CT 06401 Phone: 203-562-9700 Fax: 203-782-6285 |
Richard A. Brogadir, D.m.d. P.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 258 Wakelee Ave, Ansonia, CT 06401 Phone: 203-736-2961 |
News Archive
Study looks at type I diabetes and COVID-19
Researchers from the United States have analyzed the information on type I diabetics and COVID-19. Their study titled, "Type 1 Diabetes and COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the U.S.," is published in the latest issue of the journal Diabetes Care.
Post-menopausal women with CAD are at increased risk for SCD: Study
A new study from the Perelman School of Medicine at the University of Pennsylvania indicates that post-menopausal women with coronary artery disease and other risk factors are at an increased risk for sudden cardiac death.
Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals
Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.
New method of predicting rheumatoid arthritis offers early help to sufferers
Dutch researchers believe they may have come up with a new way of predicting whether patients with arthritic symptoms will progress to the autoimmune form of the disease, rheumatoid arthritis.
Scientists warn of urban malaria in Africa and South East Asia
Scientists at the Liverpool School of Tropical Medicine are alerting the world to what they see as a new emerging tropical disease - that of urban malaria in Africa and South East Asia.
› Verified 7 days ago